Myeloproliferative Neoplasms (MPN)

Latest News

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com

AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com

QRISK3 Tool Predicts Thrombotic Events in ET, PV

By Jared Kaltwasser

August 8th 2025

The researchers emphasized the importance of preventing bleeding events through personalized use of antiplatelet or cytoreductive therapies and closer monitoring of high-risk patients. | Image credit: Matthieu - stock.adobe.com

Hemorrhagic Events After Essential Thrombocythemia Diagnosis Strongly Linked to Early Death

By AJMC Contributor

July 29th 2025

In a novel finding, the study pinpointed 2 independent risk factors for AF development in this population: elevated interleukin-1β and TET2 mutation. | Image credit: mdaros - stock.adobe.com

Study Identifies Potential Genetic Drivers, Targeted Treatments for AF in MPN

By AJMC Contributor

July 27th 2025

Regarding survival, outcomes were similar to those seen in clinical trials of ruxolitinib for myelofibrosis. | Image credit: fotogurmespb - stock.adobe.com

Ruxolitinib Shows Sustained Clinical, QOL Benefits in MPN Real-World Data

By Rose McNulty

July 18th 2025

<1 2 3

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions